Tags: Drug.
Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.Tildrakizumab was designed to block interleukin-23 a cytokine that plays an important role in managing the immune system and autoimmune disease. Originally developed by Schering-Plough this drug is now part of Merck’s clinical program following that company’s acquisition of Schering-Plough.As of March 2014 the drug was in phase III clinical trials for plaque psoriasis.